Epoch Investment Partners Inc. Cuts Stake in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Epoch Investment Partners Inc. has reduced its stake in Supernus Pharmaceuticals by 48.4%, now owning 44,184 shares valued at approximately $1.45 million.
• Supernus Pharmaceuticals received a positive rating update from Wall Street analysts, with two firms upgrading it to a "buy" rating and a price target increase to $46.00.
• Insider transactions saw Director Bethany Sensenig and Director Frederick M. Hudson sell shares, leading to a significant decrease in their stakes, with insiders selling nearly 180,000 shares recently.

Epoch Investment Partners Inc. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 48.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 44,184 shares of the specialty pharmaceutical company's stock after selling 41,507 shares during the quarter. Epoch Investment Partners Inc. owned approximately 0.08% of Supernus Pharmaceuticals worth $1,447,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $25,000. Financial Management Professionals Inc. purchased a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $30,000. Versant Capital Management Inc increased its holdings in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 1,109 shares during the period. GF Fund Management CO. LTD. purchased a new position in Supernus Pharmaceuticals during the fourth quarter valued at approximately $42,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $41,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Piper Sandler lifted their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Friday. Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $43.00.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN traded up $0.26 on Tuesday, reaching $45.38. 224,165 shares of the company's stock traded hands, compared to its average volume of 636,127. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of 39.51 and a beta of 0.79. The stock has a 50 day moving average price of $36.89 and a 200-day moving average price of $33.91. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $45.94.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 5,369 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Frederick M. Hudson sold 7,457 shares of the company's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director owned 46,307 shares of the company's stock, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 179,606 shares of company stock valued at $7,617,005 over the last ninety days. Corporate insiders own 8.80% of the company's stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.